A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
Latest Information Update: 16 May 2023
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 05 May 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Feb 2023 Planned initiation date changed from 1 Dec 2022 to 24 Feb 2023.
- 17 Jun 2022 Planned initiation date changed from 30 Apr 2022 to 1 Dec 2022.